Journal article icon

Journal article

Rationale and design of the EXenatide study of cardiovascular event lowering (EXSCEL) trial

Abstract:

Exenatide once-weekly is an extended release formulation of exenatide, a glucagon-like peptide–1 receptor agonist, which canimprove glycemic control, body weight, blood pressure, and lipid levels in patients with type 2 diabetes mellitus (T2DM). TheEXenatide Study of Cardiovascular Event Lowering (EXSCEL) will compare the impact of adding exenatide once-weekly to usualcare with usual care alone on major cardiovascular outcomes.EXSCEL is an academically led, phase III/IV, double-blind, pragmat...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1016/j.ahj.2015.12.009

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
RDM
Sub department:
OCDEM
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
RDM
Sub department:
OCDEM
Role:
Author
Expand authors...
Publisher:
Elsevier Publisher's website
Journal:
American Heart Journal Journal website
Volume:
174
Pages:
103-110
Publication date:
2015-12-21
Acceptance date:
2015-12-14
DOI:
EISSN:
1097-6744
ISSN:
0002-8703
Pmid:
26995376
Source identifiers:
611243
Language:
English
Keywords:
Pubs id:
pubs:611243
UUID:
uuid:38012ace-45f6-47fd-b797-03a947e229d3
Local pid:
pubs:611243
Deposit date:
2017-05-30

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP